349 related articles for article (PubMed ID: 30902877)
1. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During
Hagmarker L; Svensson J; Rydén T; van Essen M; Sundlöv A; Gleisner KS; Gjertsson P; Bernhardt P
J Nucl Med; 2019 Oct; 60(10):1406-1413. PubMed ID: 30902877
[TBL] [Abstract][Full Text] [Related]
2. SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [
Blakkisrud J; Peterson AB; Wildermann SJ; Kingkiner G; Wong KK; Wang C; Frey KA; Stokke C; Dewaraja YK
J Nucl Med; 2024 May; 65(5):753-760. PubMed ID: 38548350
[TBL] [Abstract][Full Text] [Related]
3. Segmentation of Whole-Body Images into Two Compartments in Model for Bone Marrow Dosimetry Increases the Correlation with Hematological Response in
Hagmarker L; Svensson J; Rydén T; Gjertsson P; Bernhardt P
Cancer Biother Radiopharm; 2017 Nov; 32(9):335-343. PubMed ID: 29125780
[TBL] [Abstract][Full Text] [Related]
4. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
5. Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [
Hemmingsson J; Svensson J; Hallqvist A; Smits K; Johanson V; Bernhardt P
J Nucl Med; 2023 Sep; 64(9):1456-1462. PubMed ID: 37290797
[TBL] [Abstract][Full Text] [Related]
6. A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity.
Svensson J; Rydén T; Hagmarker L; Hemmingsson J; Wängberg B; Bernhardt P
EJNMMI Phys; 2016 Dec; 3(1):21. PubMed ID: 27654452
[TBL] [Abstract][Full Text] [Related]
7. A dosimetry procedure for organs-at-risk in
Marin G; Vanderlinden B; Karfis I; Guiot T; Wimana Z; Reynaert N; Vandenberghe S; Flamen P
Phys Med; 2018 Dec; 56():41-49. PubMed ID: 30527088
[TBL] [Abstract][Full Text] [Related]
8. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
[TBL] [Abstract][Full Text] [Related]
9. Deep transformer-based personalized dosimetry from SPECT/CT images: a hybrid approach for [
Mansouri Z; Salimi Y; Akhavanallaf A; Shiri I; Teixeira EPA; Hou X; Beauregard JM; Rahmim A; Zaidi H
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1516-1529. PubMed ID: 38267686
[TBL] [Abstract][Full Text] [Related]
10. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.
Sandström M; Garske-Román U; Granberg D; Johansson S; Widström C; Eriksson B; Sundin A; Lundqvist H; Lubberink M
J Nucl Med; 2013 Jan; 54(1):33-41. PubMed ID: 23223392
[TBL] [Abstract][Full Text] [Related]
11. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
[TBL] [Abstract][Full Text] [Related]
12. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
Garkavij M; Nickel M; Sjögreen-Gleisner K; Ljungberg M; Ohlsson T; Wingårdh K; Strand SE; Tennvall J
Cancer; 2010 Feb; 116(4 Suppl):1084-92. PubMed ID: 20127957
[TBL] [Abstract][Full Text] [Related]
13. A radiomic- and dosiomic-based machine learning regression model for pretreatment planning in
Plachouris D; Eleftheriadis V; Nanos T; Papathanasiou N; Sarrut D; Papadimitroulas P; Savvidis G; Vergnaud L; Salvadori J; Imperiale A; Visvikis D; Hazle JD; Kagadis GC
Med Phys; 2023 Nov; 50(11):7222-7235. PubMed ID: 37722718
[TBL] [Abstract][Full Text] [Related]
14. Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease.
Thakral P; Sen I; Das SS; Manda D; Cb V; Malik D
Br J Radiol; 2021 Oct; 94(1126):20210403. PubMed ID: 34357794
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of organ-specific dose and lesional doses following therapeutic [177Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity.
Kamaldeep ; Thapa P; Wanage G; Tervankar S; Kaisar S; Ranade R; Basu S; Das T; Banerjee S
Nucl Med Commun; 2021 Oct; 42(10):1076-1084. PubMed ID: 34528928
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
[TBL] [Abstract][Full Text] [Related]
17. Kidney dosimetry during
Sandström M; Garske-Román U; Johansson S; Granberg D; Sundin A; Freedman N
Acta Oncol; 2018 Apr; 57(4):516-521. PubMed ID: 28920501
[TBL] [Abstract][Full Text] [Related]
18. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
19. Effect of calculation method on kidney dosimetry in
Heikkonen J; Mäenpää H; Hippeläinen E; Reijonen V; Tenhunen M
Acta Oncol; 2016; 55(9-10):1069-1076. PubMed ID: 27219529
[TBL] [Abstract][Full Text] [Related]
20. Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [
Hebert K; Santoro L; Monnier M; Castan F; Berkane I; Assénat E; Fersing C; Gélibert P; Pouget JP; Bardiès M; Kotzki PO; Deshayes E
J Nucl Med; 2024 Apr; ():. PubMed ID: 38637144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
